Effect of Sertraline in treatment of Covid-19

Phase 3

Not yet recruiting

• Conditions: Covid-19.; COVID-19 , virus identified; U07.1

• Registration Number: IRCT20220110053681N1
• Lead Sponsor: Sabzevar University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 4 April 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients 18-65 years old with Covid-19 need to be hospitalized
Patient consent to participate in the study

Exclusion Criteria

Effective underlying diseases as a result of the study, whether previous cardiovascular or pulmonary diseases or other diseases and special conditions such as diabetes, weakened immune system and pregnancy
History of psychiatric illness or previous use of SSRIs including Sertraline

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Duration of hospitalization. Timepoint: Daily, during the hospitalization period. Method of measurement: Patient clinical information collection form.;Requires ICU care. Timepoint: Daily, during the hospitalization period. Method of measurement: Patient clinical information collection form.;Oxygen Saturation. Timepoint: Daily, during the hospitalization period. Method of measurement: Patient clinical information collection form.;Respiratory rate. Timepoint: Daily, during the hospitalization period. Method of measurement: Patient clinical information collection form.;Type of oxygen therapy. Timepoint: Daily, during the hospitalization period. Method of measurement: Patient clinical information collection form.;Death. Timepoint: Daily, during the hospitalization period. Method of measurement: Patient clinical information collection form.